Clinical Trial Evaluating Safety and Efficacy of Resomelagon on Dengue Infection (RESOVIR-2)
120 patients around the world
Available in Brazil
Federal University of Minas Gerais
120Patients around the world
This study is for people with
Dengue
Requirements for the patient
To 65 Years
All Gender
Medical requirements
Patients who are 18 to 65 years old.
Able to understand study procedures and give informed consent.
Presents with more than 36 and less than 84h since symptoms onset.
Symptoms compatible with dengue infection (fever, myalgia, arthralgia, headache or conjunctivitis) with positive antigen test or polymerase chain reaction test.
Has any comorbidity which is perceived as significant by the investigator.
Significant laboratory abnormalities discovered at triage: Hemoglobin <10g/dL; Platelet count < 50.000/microL; alanine transaminase > 3x upper limit of normal; Total bilirubin >1.5 x upper limit of normal; glomerular filtration rate < 60mls/min/1.73m2.
Contraindications or known hypersensitivity to Resomelagon.
Presents as dengue with warning signs or severe dengue at inclusion.
Currently participating in another drug clinical trial.
Clinical evidence of another infection that might explain current symptoms.
Pregnant women or women actively trying to achieve pregnancy.